Maze Therapeutics, Inc. MAZE 深 沪
已收盘 10-31 16:00:00 美东时间
32.91
-0.310
-0.93%
华盛通- 最 高33.91
- 今 开33.51
- 成交量 17.69万股
- 最 低 32.33
- 昨 收 33.22
- 总市值 14.43亿
- 52周最高 34.29
- 市盈率 静 423.01
- 换手率 0.40%
- 52周最低 6.71
- 委 比 -48.94%
- 总股本 4385.09万
- 历史最高 34.29
- 量 比 0.63
- 振 幅 4.76%
- 历史最低 6.71
- 每 手 1
- 风险率 6.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
South San Francisco-based Maze Therapeutics has appointed Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D. Hoppenot brings over three decades of experience in biotech, having previously led Incyte Corporation to significant growth. Maze, focused on developing precision medicines for kidney and metabolic diseases, highlighted its promising first-in-human data for MZE782, a recent $150 million private placement, ...
10-06 11:00
Analysts’ Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
10-02 17:20
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
美股周涨跌榜 | 好莱坞或迎巨震！华纳兄弟探索频道周涨超55%；新思科技绩后暴跌28.9%
好莱坞或迎巨震！华纳兄弟探索频道周涨超55%，传Paramount Skydance拟收购公司；新思科技绩后暴跌28.9%>>
09-13 11:42
美股牛股 | 网红股OpenDoor一夜飙升近80%！公司高管团队调整
网红股OpenDoor一夜飙升近80%！公司高管团队调整；传埃里森家族正筹备收购，华纳兄弟探索频道大涨超29%>>
09-12 14:23
Maze Therapeutics Advances Clinical Programs Amid Financial Stability
Maze Therapeutics, Inc. ( ($MAZE) ) has released its Q2 earnings. Here is a bre...
09-12 11:57
Maze Therapeutics rises on $150M equity offering
Maze Therapeutics (NASDAQ:MAZE) shares rose over 45% premarket on Thursday after the biopharmaceutical company announced an oversubscribed private placement of its securities to raise gross proceeds o...
09-11 19:45
Maze Therapeutics Secures $150M In Oversubscribed Private Placement
Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a
09-11 19:37
